Technische Universität München
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22779 - email: presse@tum.de - web: www.tum.de Image download: https://mediatum.ub.tum.de/652209?show_id=1691364 NEWS RELEASE Alzheimer's disease and type 2 diabetes: Synthetic peptides may suppress formation of harmful amyloid ...
Vienna (ots) - Success Story of Extracorporeal Shock Wave Therapy (ESWT) Successful for over 40 years in urology for the disintegration of kidney stones, with high efficiency and hardly any side effects worth mentioning. How does the shock wave work? Without causing mechanical damage, shockwaves trigger a biological ...
From their birth through to their death, cells lead an eventful existence. Thanks to single-cell genomics, their destiny in large cell populations can now be analyzed. However, this method destroys the cell, which makes it difficult to draw conclusions about the dynamics of cell ...
As a result of digitalization, research is producing ever larger and more complex data sets. While these hold great potential for example for biomedicine, energy research, geo-research or robotics, they also need to be managed and interpreted. To address this need, the Munich School for Data Science @ Helmholtz, TUM & LMU (MuDS) has ...
Munich, Germany (ots/PRNewswire) - - TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care MUNICH, Germany, August 31 /PRNewswire/ -- - For non-US Healthcare Media The results of the ...
Berlin (ots/PRNewswire) - - For non-US Healthcare Media and non-UK Healthcare Media - New Studies Show Benefits of MICARDIS(R) (Telmisartan) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS(R) (telmisartan) in free combination with amlodipine or fixed combination with hydrochlorothiazide (HCTZ) 25 mg confirm that a ...
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media, Outside the US Only Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus(R) 80/25 in all 27 EU member states. It ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from ...
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
Giessen, Germany (ots) - Diabetes mellitus and cancer are among the diseases of greatest clinical focus. At the ScheBo Biotech AG Symposium during MEDICA on the occasion of the World Congress of Pathology and Laboratory Medicine (WASPaLM) 2001 two specific diagnostic tools with unique clinical approaches will be ...
